Advertisement

Topics

Novartis AG Company Profile

22:12 EDT 25th September 2017 | BioPortfolio

Novartis's name, derived from the Latin novae artes, means "new skills" and reflects Novartis's commitment to focus research and development to bring new healthcare products to the patients and physicians. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world.

Location

Basel
CH-4002
Switzerland

Contact

Phone: +41 61 324 11 11
Fax: +41 61 324 80 01


News Articles [1110 Associated News Articles listed on BioPortfolio]

Novartis: Dividendengarant mit Produktoffensive

Die Meldungen reißen derzeit beim Schweizer Pharmakonzern Novartis nicht ab. Zuletzt hat Novartis vielversprechende Studiendaten zu seinem Produktkandidaten AMG 334 (Erenumab) zur Behandlung von Mi.....

Novartis: Neue Impulse

Die Analysten von Kepler Cheuvreux bleiben bei der Kaufempfehlung für die Aktien von Novartis. Verändert wird hingegen das Kursziel für die Schweizer Aktie. Bisher lag dieses für die Novartis-Papi...

Press Release: Novartis presents data -2-

Press Release: Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting Novartis International AG / Novartis prese...

Novartis appoints Bertrand Bodson as Chief Digital Officer

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO ...

FDA to review Novartis CAR-T next month

FDA advisers will meet in July to begin their review of Novartis' CAR-T therapy tisagenlecleucel-T (CTL 109). This will make the drug the first CAR-T candidate to be scrutinised by the FDA’s ...

Jefferies hebt Ziel für Novartis auf 100 Franken - 'Buy'

Das Analysehaus Jefferies hat das Kursziel für Novartis von 95 auf 100 Franken angehoben und die Einstufung auf "Buy" belassen. Novartis gehöre neben anderen Pharmakonzernen wie Abbvie , Bayer ode.....

Jimenez to Quit Novartis Next Year

Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based drugnaker in early 2018, after eight years at the helm, and return to his native US. However, he will remain "available for...

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug.   At the 2017 Annual European Congress of Rheu...

PubMed Articles [11 Associated PubMed Articles listed on BioPortfolio]

Google, Novartis back Medicxi's ambitions.

Novartis snaps up Selexys for sickle cell.

First approval in sight for Novartis' CAR-T therapy after panel vote.

Patent trend and competitive analysis of cancer immunotherapy in the United States.

Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the ...

Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.

The distribution and use of substandard medicines (SSMs) is a public health concern worldwide. The detection of SSMs is currently limited to expensive large-scale assay techniques such as high-perform...

Clinical Trials [89 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive f...

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines

This study will evaluate the safety, tolerability and immunogenicity of one or two 0.25mL or 0.5mL intramuscular injections of influenza vaccine compared with control vaccine in subjects 6...

Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study

The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, ...

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

This study is aimed to evaluate safety, tolerabilty and immunogenicity of three doses of Novartis Meningococcal B vaccine and of one dose of Novartis Menongococcal ACWY vaccine when adnmi...

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would b...

Companies [87 Associated Companies listed on BioPortfolio]

Novartis Consumer Health

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innova...

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG

Novartis AG

Novartis's name, derived from the Latin novae artes, means "new skills" and reflects Novartis's commitment to focus research and development to bring new healthcare products to the...

Novartis Vaccines and Diagnostics

Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease. Through industry-leading scientific expertise, the company is focused on extending critical ...

Idenix Pharmaceuticals

Idenix is pursuing a disciplined business strategy that seeks to capitalize upon the diverse expertise of the company’s management team. While Idenix is focused on bringing its late-stage product ca...

More Information about "Novartis AG" on BioPortfolio

We have published hundreds of Novartis AG news stories on BioPortfolio along with dozens of Novartis AG Clinical Trials and PubMed Articles about Novartis AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novartis AG Companies in our database. You can also find out about relevant Novartis AG Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...


Corporate Database Quicklinks



Searches Linking to this Company Record